BUNNAGE MARK E. (EVP, Chief Scientific Officer) sold 7.8% of their position (620.00 shares) of VERTEX PHARMACEUTICALS INC / MA on the open market
Open‑market sale worth $301.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/26/2026ACC: 0000875320-26-000112
Officer· EVP, Chief Scientific Officer
Since Feb 2026
-1.20K
Net shares
Net seller
$583.9K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
1.20K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−582.00
Price / share
$485.11
Trade value
$282.33K
% of position
6.9%
2/24/2026
8.49K→7.90K
Common Stock
Direct
Shares
−620.00
Price / share
$486.35
Trade value
$301.54K
% of position
7.8%
2/25/2026
7.90K→7.28K
Total
Net shares
−1.20K
Net value
-$583.87K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/24/2026 | F · Tax Withholding | −582.00 | $485.11 | $282.33K | 6.9% | 8.49K | 7.90K |
| Common Stock Direct | 2/25/2026 | S · Sale | −620.00 | $486.35 | $301.54K | 7.8% | 7.90K | 7.28K |
| Total | −1.20K | -$583.87K | ||||||
Derivative Transactions0
No derivative transactions reported